Showing posts with label Biotechnology News. Show all posts
Showing posts with label Biotechnology News. Show all posts

Monday, September 22, 2014

Brinks Attorney Jennifer Fox to Address Recent Biotech Patent Litigation at BIO IP & Diagnostics Symposium





CONTACT
Cheryl Kennedy
Clovis, Inc.
312.346.1700 x2002

ckennedy@clovisinc.com

Risa McMahon
Brinks Gilson & Lione
312.840.3172
rmcmahon@brinksgilson.com


DURHAM, N.C.—Jennifer L. Fox, a patent attorney at Brinks Gilson & Lione, one of the largest intellectual property law firms in the United States, will be a featured speaker at BIO's 2nd Annual IP & Diagnostics Symposium (BIO IPDX) on Friday, September 26, 2014 at the Hilton Alexandria Old Town in Alexandria, Va.

Fox will present "Recent Patent Litigation and Disputes" with a panel of biotechnology and IP law professionals that will discuss the implications for the biotech industry of the decisions of the U.S. Supreme Court's decisions in the Myriad and Prometheus cases, along with other recent decisions and ongoing cases.

Fox focuses her practice on counseling pharmaceutical and biotechnology companies in patent and related transactional matters. Both a research scientist and patent attorney, she has over 17 years of experience in the pharmaceutical and biotechnology industries. She is Of Counsel in Brinks' office in Research Triangle Park, N.C.

BIO IPDX will review the current patent law landscape and evaluate its impact on both the genetic diagnostics and biopharmaceutical sectors. The program will explore IP issues for both general and companion diagnostics, as well as potential regulatory dimensions. The symposium is geared towards patent practitioners in the life sciences, both in-house and in private practice, as well as in-house regulatory affairs staff, licensing professionals, business development executives, and regulatory agency staff seeking to understand pre-marketing and intellectual property challenges in the area of diagnostics.

Although there is no fee to attend, reservations are required. For more information and to register, contact Caroline Arrington at carrington@bio.org or (202) 962-9228.


Brinks Gilson & Lione
Brinks Gilson & Lione has 160 attorneys, scientific advisors and patent agents who specialize in intellectual property, making it one of the largest intellectual property law firms in the U.S. Clients around the world use Brinks to help them identify, protect, manage and enforce their intellectual property. Brinks lawyers provide expertise in all aspects of patent, trademark, unfair competition, trade secret and copyright law. The Brinks team includes lawyers with advanced degrees in all fields of technology and science. Based in Chicago, Brinks has offices in Washington, D.C., Research Triangle Park, N.C., Ann Arbor, Detroit, Salt Lake City and Indianapolis. More information is at www.brinksgilson.com. 

Tuesday, July 1, 2014

Arbovax Closing In On Vaccine For Chikungunya


RALEIGH, N.C., June 19, 2014 – Arbovax, Inc., a clinical stage biotechnology company, has successfully demonstrated in an animal model the efficacy of its vaccine technology for the treatment of Chikungunya, a mosquito borne virus that has recently emerged in the US.  “There was a major outbreak in the Caribbean that started last December in St Martin and quickly spread to other islands. To date there has been over 130,000 cases, so it was only a question of time before it came to the US and we have an effective means to combat it,” said Arbovax CEO Malcolm Thomas.

According to the Center for Disease Control and Prevention, as of June 17, 2014 there are 80 confirmed cases of Chikungunya in thirteen states, Puerto Rico and the US Virgin Islands.  Fifty seven of those cases are in people who recently visited the Caribbean. Once a person becomes infected, there’s an incubation period of three to seven days.  The most common signs of the virus are fever and multiple joint pains. The virus is not usually fatal but extremely painful; it arose in Africa in the 1950s, the name “Chikungunya” comes from the Makonde language meaning ‘bent out of shape” describing the contortion brought on by the pain of the virus.

The Arbovax core technology is a whole virus vaccine developed by Drs. Dennis Brown and Raquel Hernandez of North Carolina State University. In animal tests, the vaccine has shown that it can provide a practical and cost-effective means to fight chikungunya and other mosquito borne viral diseases such as dengue fever, West Nile, Japanese encephalitis, and yellow fever.


Contact:

Malcolm Thomas

President and CEO
Arbovax, Inc.
(919) 655 0412 x301
mthomas@arbovax.com
www.arbovax.com

Friday, June 27, 2014

Top U.S. Life Sciences Clusters Revealed (Raleigh-Durham #4)



JLL’s 2014 Global Life Sciences Cluster Report identifies the top U.S. cities for biotech business and research
SAN DIEGO, June 25, 2014 – Global shifts in the life sciences landscape may be rewriting the global map, but U.S. cities continue to lead the world in biopharmaceutical resources and enterprises. Access to talent and research is keeping cities like Boston, San Francisco and San Diego at the top of the U.S. life sciences clusters list. Factors shaping these clusters, and the city rankings, were revealed in JLL’s third annual Global Life Sciences Cluster Report released today at the BIO International Convention.

"The right-sizing and reshuffling of the global biopharmaceutical companies has left its mark on key U.S. cities,” said Roger Humphrey, Executive Managing Director of JLL’s Life Sciences group. “The strongest U.S. clusters have retained their competitive advantages, and continue to thrive as top centers of talent and innovation."

The 2014 JLL Global Life Sciences Cluster Report analyses top U.S. life sciences clusters, ranks the cities for their prominence in the industry and also offers an analysis of global trends in 17 countries.

Top U.S. life sciences clusters

U.S. life sciences clusters with a large presence of small start-ups, mid-tier biotech firms and specialty companies flourished in 2013, with moderate increases in year-on-year employment and establishments. Conversely, clusters with a major-tenant base, such as large headquarter campuses or manufacturing sites, generally experienced declining employment. Below is the 2014 ranking of the top 10 U.S. life sciences clusters:

Rank
2014 Cluster Report (current)
2013 Cluster Report
Year-Over-Year Trends
1
Greater Boston (no change)
Greater Boston
·  Across the board, small and mid-size companies are driving most facility development and leasing transactions.
·  Boston remains the clear world leader.
·  San Diego’s ranking drop is largely due to reduced demand for resources by mature companies as smaller enterprises have flourished.
·  Despite HQ relocations and consolidations, New Jersey/NYC/Westchester gained in rank.
·  No new additions or drop-offs to the Top 10.

2
San Francisco Bay Area (+1)
San Diego
3
San Diego (-1)
San Francisco Bay Area
4
Raleigh-Durham (no change)
Raleigh-Durham
5
New Jersey/NYC/Westchester (+2)
Philadelphia
6
Los Angeles/Orange County (+2)
Washington D.C. Metro Area
7
Philadelphia (-2)
New Jersey / New York City
8
Suburban Maryland/Metro Washington DC (-2)
Los Angeles / Orange County
9
Minneapolis/St. Paul (no change)
Minneapolis-St. Paul
10
Seattle (no change)
Seattle
Source: JLL 2014 Global Life Sciences Cluster Report


Boston continues to lead in life sciences resources

The Greater Boston Area once again tops the U.S cluster scorecard. Although San Diego and the San Francisco Bay Area reported higher year-over-year employment growth, Boston’s ability to attract venture capital and U.S. National Institutes of Health funding secures its position as the top life sciences cluster in the world. All three cities are expected to lead the United States’ life sciences industry in the coming years because of the critical mass of start-ups and mid-tier companies, leading research institutions, access to private and public funding, and local leaders focused on growing their life sciences industries. Across the board, small and mid-size companies are driving most facility development and leasing transactions.

Global shifts in innovation, markets 
Following the “gloom and doom” era of patent expirations, depleted product pipelines and uncertainty in U.S. healthcare reform, 2013 brought new energy to the life sciences sector. As Big Pharma retrenches, small- to medium-sized companies and specialty players are steadily growing, propelling initial public offerings to a volume not seen in years.

As detailed in the 2011 Global Life Sciences Cluster Report, the life sciences industry’s move to more profitable models has led to a facilities footprint evolution. More than a third of life sciences companies anticipate reducing or consolidating their real estate portfolios in European markets, while shifting production facilities or even entire business units and R&D centers to emerging markets, according to JLL’s 2014 Corporate Real Estate Trends for the Life Sciences Sector survey of corporate real estate executives.

The need for strategic corporate real estate portfolio planning is at an all-time high, as companies of all sizes seek operating efficiencies. Beyond strategic site selection, the life sciences sector has become the most active in outsourcing portfolio and facilities management, according to the Corporate Real Estate Trends report, with 22 percent fully outsourcing these functions, compared to 13 percent in other industries. Facilities management outsourcing is expected to grow in the life sciences sector in the next three years, expanding “beyond the yellow line” to encompass management of laboratory and production equipment, hazardous waste, supply chain, facilities regulatory compliance and other critical areas.

About the Report
JLL’s annual Global Life Sciences Cluster Report tracks geographic shifts in life sciences innovation, operations and facilities investments, including analysis of countries and cities most actively investing in their life sciences sectors. It includes a ranking of the top U.S. life sciences clusters, as well as analyses of life science hotspots around the world. The complete findings of the Global Life Sciences Cluster Report are available in a dedicated microsite here:  http://www.jll.com/cluster-report.

JLL offers a team of real estate and facility management experts dedicated to helping life sciences companies optimize and manage their real estate portfolios. The firm provides a comprehensive range of facilities management services to the life sciences community covering 75 million square feet of research, manufacturing and commercial space. Its industry leading full-service platform includes: integrated facilities management, engineering and operations, energy and sustainability, transaction advisory services, lease administration, project management and a platform for comprehensive laboratory services, Labwell.

A leader in the real estate outsourcing field, JLL’s Corporate Solutions business helps corporations improve productivity in the cost, efficiency and performance of their national, regional or global real estate portfolios by creating outsourcing partnerships to manage and execute a range of corporate real estate services. This service delivery capability helps corporations improve business performance, particularly as companies turn to the outsourcing of their real estate activity as a way to manage expenses and enhance profitability.
 
For more news, videos and research resources on JLL, please visit the firm’s global media center Web page http://bit.ly/18P2tkv.

About JLL
JLL (NYSE: JLL) is a professional services and investment management firm offering specialized real estate services to clients seeking increased value by owning, occupying and investing in real estate. With annual fee revenue of $4 billion, JLL has more than 200 corporate offices and operates in 75 countries worldwide. On behalf of its clients, the firm provides management and real estate outsourcing services for a property portfolio of 3 billion square feet and completed $99 billion in sales, acquisitions and finance transactions in 2013. Its investment management business, LaSalle Investment Management, has $48.0 billion of real estate assets under management. JLL is the brand name of Jones Lang LaSalle Incorporated. For further information, visit www.jll.com.

Contact:
Rebecca Taylor
 +1 312 228 2817
Jennifer Harris
+1 224 619 2190